Stem Cell Innovations signs compound validation collaboration with H. Lundbeck

Published: 8-May-2007
Sustainability Research & Development

Stem Cell Innovations (SCI), a cell biology company with an office in Scotch Plains, New Jersey, and facilities in Houston, Texas and in Leiden, the Netherlands, has entered into an agreement to examine hepatic metabolism of a set of Lundbeck compounds using its proprietary C3A human liver cell-line.


Stem Cell Innovations (SCI), a cell biology company with an office in Scotch Plains, New Jersey, and facilities in Houston, Texas and in Leiden, the Netherlands, has entered into an agreement to examine hepatic metabolism of a set of Lundbeck compounds using its proprietary C3A human liver cell-line.

Lundbeck is a Danish research-based pharmaceutical company, engaged in research to find new drugs for treatment of CNS disorders.

C3A is SCI's patented human liver cell line, originally developed for use in an artificial liver used to support patients waiting for transplantation. The cells exhibit a wide variety of human liver functions and are ideal for use in examining the effects of new drugs on the human liver. The application of SCI's ACTIVTox system, based on the C3A cell line, can lead to better drugs with a decreased likelihood of causing liver toxicity.

'This new collaboration shows the expanding acceptance of our C3A cell-line as a platform to study human liver function,' said SCI's' ceo Dr James Kelly. 'Our protected C3A cell system has intact human liver machinery, is robust and thoroughly quality controlled - all the prerequisites for larger scale in vitro efficacy and safety programmes.'

See more

You may also like

Media

Domain Therapeutics receives $125m to assign its intellectual property

Read more
Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  3. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Media

Domain Therapeutics receives $125m to assign its intellectual property

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Research & Development

Lundbeck secures funding from The Michael J Fox Foundation

Receives DKK5.5m to support two Danish research projects in Parkinson\'s Disease
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Drug approvals: more numerous but niche

After many years of low approval rates, in 2012 more than 30 new drugs were approved by the European Medicines Agency. Although many of them were niche products, some were for diseases with large patient populations, such as diabetes and various forms of cancer
Regulatory

Antidepressant – vortioxetine

The majority of modern depression and anxiety treatments modulate the serotonin, or 5-HT, signalling pathways. However, response can be variable so there is still room in the market for alternatives
Research & Development

Lundbeck and Otsuka to deliver psychiatric products

Danish firm will pay up to US$1.8bn to Otsuka
Research & Development

Lundbeck sets up research centre in Shanghai

To build partnerships with businesses and universities in the region
Subscribe now